0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      ACE Inhibitors in Hypertension: A US Perspective

      Cardiology

      S. Karger AG

      ACE inhibitors, Hypertension

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The failure of recent antihypertensive trials to document clearly a reduction in the risk of coronary heart disease (nonfatal or fatal myocardial infarction and sudden death) has important clinical implications. Although the causes of this phenomenon are unknown, it is possible that lipid and metabolic side effects of the antihypertensive drugs used in these studies negated the beneficial effects of blood pressure reduction. Angiotensin-converting enzyme (ACE) inhibitors are lipid neutral and associated with few metabolic side effects, and may be considered over agents that cause adverse effects on such parameters as serum cholesterol, glucose, potassium, and uric acid levels. ACE inhibitors are now emerging in the United States as important first-line therapy for the treatment of hypertension.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5062-8
          978-3-318-01590-4
          0008-6312
          1421-9751
          1989
          1989
          12 November 2008
          : 76
          : Suppl 2
          : 23-30
          Affiliations
          Division of Vascular Medicine and Atherosclerosis, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass., USA
          Article
          174556 Cardiology 1989;76:23–30
          10.1159/000174556
          2670218
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          ACE-Inhibition: State of the Art

          Comments

          Comment on this article